News Focus
News Focus
icon url

Lishur

01/04/24 9:27 AM

#2834 RE: DewDiligence #2833

Interesting and I hope its good to the ear of the market....
icon url

DC15

01/04/24 12:00 PM

#2837 RE: DewDiligence #2833

Is it likely that an agent from this program could be used to counter the itch associated with their MASLD candidates?
icon url

vinmantoo

01/04/24 12:11 PM

#2839 RE: DewDiligence #2833

ENTA’s new non-virology program is in immunology:



Thanks Dew. Looks like the tax loss selling of ENTA might be finally over as the price has risen over $11, something we haven't seen since September. Higher than normal today based on the announcement the new oral KIT inhibitor drug. I don't if I end up missing my chance to garner some losses for tax purposes. So it looks like betting on a company with great chemists and leadership along with being stubborn just might end up paying off.

Now we just need to read that PFE decided to settle in the patent lawsuit over Paxlovid and grants ENTA a milestone payments and a percentage of future earnings. If that happens, then Ralph Kramden will be describing ENTA's trajectory.